301 related articles for article (PubMed ID: 25754604)
1. Detection of fetal chromosomal anomalies: does nuchal translucency measurement have added value in the era of non-invasive prenatal testing?
Lichtenbelt KD; Diemel BD; Koster MP; Manten GT; Siljee J; Schuring-Blom GH; Page-Christiaens GC
Prenat Diagn; 2015 Jul; 35(7):663-8. PubMed ID: 25754604
[TBL] [Abstract][Full Text] [Related]
2. First-trimester screening for trisomies 18 and 13, triploidy and Turner syndrome by detailed early anomaly scan.
Wagner P; Sonek J; Hoopmann M; Abele H; Kagan KO
Ultrasound Obstet Gynecol; 2016 Oct; 48(4):446-451. PubMed ID: 26611869
[TBL] [Abstract][Full Text] [Related]
3. Prenatal screening for fetal aneuploidy in singleton pregnancies.
Chitayat D; Langlois S; Douglas Wilson R; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
[TBL] [Abstract][Full Text] [Related]
4. Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test.
Gil MM; Revello R; Poon LC; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Jan; 47(1):45-52. PubMed ID: 26498918
[TBL] [Abstract][Full Text] [Related]
5. Screening for trisomies by cell-free DNA testing of maternal blood: consequences of a failed result.
Revello R; Sarno L; Ispas A; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Jun; 47(6):698-704. PubMed ID: 26743020
[TBL] [Abstract][Full Text] [Related]
6. First-trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free β-hCG and PAPP-A: a 5-year prospective study.
Ghaffari SR; Tahmasebpour AR; Jamal A; Hantoushzadeh S; Eslamian L; Marsoosi V; Fattahi F; Rajaei M; Niroomanesh S; Borna S; Beigi A; Khazardoost S; Saleh-Gargari S; Rahimi-Sharbaf F; Farrokhi B; Bayani N; Tehrani SE; Shahsavan K; Farzan S; Moossavi S; Ramezanzadeh F; Dastan J; Rafati M
Ultrasound Obstet Gynecol; 2012 May; 39(5):528-34. PubMed ID: 21793085
[TBL] [Abstract][Full Text] [Related]
7. Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting.
Miltoft CB; Rode L; Ekelund CK; Sundberg K; Kjaergaard S; Zingenberg H; Tabor A
Ultrasound Obstet Gynecol; 2018 Apr; 51(4):470-479. PubMed ID: 28640470
[TBL] [Abstract][Full Text] [Related]
8. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of first-trimester combined test in screening for trisomies 21, 18 and 13.
Santorum M; Wright D; Syngelaki A; Karagioti N; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Jun; 49(6):714-720. PubMed ID: 27549925
[TBL] [Abstract][Full Text] [Related]
10. Should cell-free DNA testing be used in pregnancy with increased fetal nuchal translucency?
Miranda J; Paz Y Miño F; Borobio V; Badenas C; Rodriguez-Revenga L; Pauta M; Borrell A
Ultrasound Obstet Gynecol; 2020 May; 55(5):645-651. PubMed ID: 31301176
[TBL] [Abstract][Full Text] [Related]
11. First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing.
Wright D; Syngelaki A; Bradbury I; Akolekar R; Nicolaides KH
Fetal Diagn Ther; 2014; 35(2):118-26. PubMed ID: 24356462
[TBL] [Abstract][Full Text] [Related]
12. Routine first-trimester screening for fetal trisomies in twin pregnancy: cell-free DNA test contingent on results from combined test.
Galeva S; Konstantinidou L; Gil MM; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2019 Feb; 53(2):208-213. PubMed ID: 30353581
[TBL] [Abstract][Full Text] [Related]
13. Prenatal diagnosis of fetuses with increased nuchal translucency using an approach based on quantitative fluorescent polymerase chain reaction and genomic microarray.
Pan M; Han J; Zhen L; Yang X; Li R; Liao C; Li DZ
Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():164-7. PubMed ID: 26771907
[TBL] [Abstract][Full Text] [Related]
14. Improved diagnostic accuracy by using secondary ultrasound markers in the first-trimester screening for trisomies 21, 18 and 13 and Turner syndrome.
Karadzov-Orlic N; Egic A; Milovanovic Z; Marinkovic M; Damnjanovic-Pazin B; Lukic R; Joksic I; Curkovic A; Mikovic Z
Prenat Diagn; 2012 Jul; 32(7):638-43. PubMed ID: 22570267
[TBL] [Abstract][Full Text] [Related]
15. Trial by Dutch laboratories for evaluation of non-invasive prenatal testing. Part I-clinical impact.
Oepkes D; Page-Christiaens GC; Bax CJ; Bekker MN; Bilardo CM; Boon EM; Schuring-Blom GH; Coumans AB; Faas BH; Galjaard RH; Go AT; Henneman L; Macville MV; Pajkrt E; Suijkerbuijk RF; Huijsdens-van Amsterdam K; Van Opstal D; Verweij EJ; Weiss MM; Sistermans EA;
Prenat Diagn; 2016 Dec; 36(12):1083-1090. PubMed ID: 27750376
[TBL] [Abstract][Full Text] [Related]
16. [Trisomy 18 and 13 and triploidy: the best way to diagnosis].
Odeh M
Harefuah; 2014 Sep; 153(9):522-3, 559. PubMed ID: 25417487
[TBL] [Abstract][Full Text] [Related]
17. DNA sequencing versus standard prenatal aneuploidy screening.
Bianchi DW; Parker RL; Wentworth J; Madankumar R; Saffer C; Das AF; Craig JA; Chudova DI; Devers PL; Jones KW; Oliver K; Rava RP; Sehnert AJ;
N Engl J Med; 2014 Feb; 370(9):799-808. PubMed ID: 24571752
[TBL] [Abstract][Full Text] [Related]
18. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
Chen X; Chang Y; Cui HY; Ren CC; Yu BY
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
[TBL] [Abstract][Full Text] [Related]
19. [MODELS OF CLINICAL IMPLEMENTATION OF CELL FREE FETAL DNA IN THE MATERNAL SERUM SCREENING TEST-ANALYSIS].
Yankova M; Chaveeva P; Stratieva V
Akush Ginekol (Sofiia); 2015; 54(7):15-21. PubMed ID: 27025103
[TBL] [Abstract][Full Text] [Related]
20. First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing.
Kagan KO; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2015 Jan; 45(1):42-7. PubMed ID: 25307357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]